Comprehensive Immunophenotyping from a Single Slide

Protein Biomarkers
Fluorescence In Situ Hybridization
DNA Sequencing (ROI)

Low Tumor Infiltrating Lymphocytes

CD8 CD4 FOXP3 PDL-1 CK

Metastatic colon adenocarcinoma
Low number of both CD3+ | CD4+ Thelper and CD3+ | CD8+ Tcytotoxic T cells.

MultiOmyx™: Multi-Molecular Multiplexing Methodology

NeoGenomics introduces MultiOmyx, a proprietary, multiplexing methodology that enables analysis of dozens of proteins and DNA biomarkers in a single tissue section. Instead of being able to study one or two disease markers at a time, MultiOmyx studies up to 60 biomarkers in a single tumor slice. It also uncovers the relationship between markers which could yield new insights and a more complete picture of tumor behavior.

The key benefits of MultiOmyx include: